1. Scrip
  2. >>Focus On Asia

Two Chinese Biotechs Raise $104m To Challenge GSK’s Shingrix

 
• By Dexter Jie Yan

MAXVAX Biotechnology and Beijing Luzhu Biotechnology raise new funds to progress their recombinant herpes zoster vaccine candidates with novel adjuvants, while multiple other ventures in China complete new financings across multiple therapeutic areas and modalities. 

fund raising
MAXVAX and Luzhu expected to roll out vaccines to challenge GSK's Shingrix inside and outside China • Source: Alamy

Two Chinese biotechs developing recombinant herpes zoster vaccines have garnered support from venture capital and private equity firms by raising a combined more than CNY700m ($104m) over the past few weeks.

They are expected to roll out the vaccines for shingles to challenge GlaxoSmithKline Pharmaceuticals Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia